Skip to main content
PLOS One logoLink to PLOS One
. 2025 Jun 17;20(6):e0326212. doi: 10.1371/journal.pone.0326212

Integrated multi-omics analysis and predictive modeling of heart failure using sepsis-related gene signature

Yiping Lang 1, Tianyu Liang 2, Fei Li 1,*
Editor: Muhammad Iqhrammullah3
PMCID: PMC12173235  PMID: 40526611

Abstract

Background

Heart failure (HF) is characterized by complex molecular alterations, and recent studies suggest a potential role for sepsis-related genes in cardiovascular dysfunction. This study aimed to develop a predictive model for HF based on sepsis-related gene signatures.

Methods

Three sepsis-related datasets (GSE65682, GSE54514, and GSE95233) were analyzed to identify differentially expressed genes (DEGs) following batch effect correction using the ComBat algorithm. With the use of elastic net regularization and the glmnet package in R, Lasso Cox regression was employed to screen out gene signatures. A predictive model was developed based on the expression of each gene signature and the co-efficient values. In addition, the predictive model was validated on independent HF datasets (GSE57345, GSE141910, and GSE5406). Model performance was assessed through receiver operating characteristic (ROC) analysis and AUC values of each gene signature, and immune infiltration was evaluated using CIBERSORT, IPS, and xCell. Sepsis models of C57BL/6 mice were established by cecal ligation and puncture (CLP).

Results

We identified 340 up-regulated and 333 down-regulated sepsis-related genes. The predictive model, incorporating six key genes, demonstrated superior performance compared to individual genes across both training and validation datasets with the AUC value of the risk score above 0.9, significantly higher than that of a single gene. Immune infiltration profiles differed significantly between HF patients and controls, with more pronounced alterations observed at higher risk score levels. Finally, the expression of six key genes in sepsis models was confirmed to be consistent with our prediction.

Conclusion

The model constructed through sepsis-related characteristic genes provides a highly advantageous method for predicting HF, and the characteristic genes we have screened may be potential biomarkers for predicting HF. This model has potential application value in early diagnosis and risk stratification, which can help improve the clinical management of heart failure and provide new ideas for preventing HF.

1. Introduction

Sepsis is defined as a systemic inflammatory response to infection, often leading to multiple organ dysfunction, and in severe cases, progressing to septic shock. Recent updates to the diagnostic criteria for sepsis have influenced its epidemiological characteristics and clinical identification [1,2]. This systemic inflammatory burden not only affects multiple organs but also has profound implications for cardiac function. During sepsis, the inflammatory response causes an excessive production of catecholamines, which impairs myocardial function and contractility. Furthermore, when tachycardia leads to decreased coronary perfusion and cardiac output, overall cardiac output is negatively impacted [3]. Both sepsis and heart failure (HF) significantly contribute to the incidence of various complications and mortality rates. The mortality rate associated with septic shock is approximately 40% [4], while the five-year mortality rate for diagnosed HF is around 50% [5]. Notably, sepsis accounts for one-quarter of all deaths among HF patients, thereby establishing a crucial link between the occurrence or exacerbation of HF and sepsis. HF is a syndrome characterized by the heart’s inability to pump sufficient blood and oxygen to meet the metabolic demands of other organs. HF is a prevalent cardiovascular disorder that impacts the health of millions worldwide [6]. Ejection fraction (EF) is commonly used as a prognostic indicator and for the classification of HF patients, serving as a crucial clinical parameter in this context [7]. HF currently impacts approximately 64 million people worldwide, with increasing prevalence attributed to an aging population, a rising burden of HF comorbidities and risk factors, and improved survival following myocardial infarction. In clinical practice, B-type natriuretic peptide (BNP) and N-terminal pro-b-type natriuretic peptide (NT-proBNP) are regarded as gold standards for the prognostic diagnosis and stratification of HF [8]. The early use of beta-blockers and mineralocorticoid receptor antagonists (MRAs) has been shown to reduce the incidence of composite endpoints during hospitalization, as well as overall mortality, in-hospital mortality, and rates of readmission following discharge [9,10].

Sepsis significantly impairs cardiac function and often contributes to the onset of heart failure. Research has shown that impaired cardiac function in septic patients is associated with elevated levels of various biomarkers, including BNP and endothelin-1 (ET-1) [11,12]. Moreover, another study revealed that septic patients with concurrent heart failure exhibit significantly higher serum levels of CXCL8 and ET-1 compared to those with sepsis alone, suggesting that these biomarkers may play important roles in the pathophysiology of sepsis complicated by HF [12]. Given the substantial clinical overlap between sepsis and HF, understanding the molecular mechanisms linking these two conditions is vital for improving patient outcomes. Despite advancements in treatment strategies, reliable predictive models are still needed to identify the risk of HF in septic patients and to provide insights into potential therapeutic targets.

Bioinformatics enables the systematic analysis of large-scale gene expression data, revealing the complex molecular mechanisms underlying diseases [13,14]. Through the application of bioinformatics analytical methods, various biomarkers regulating the progression of HF have been identified [15–17]. Moreover, in the context of sepsis and heart failure, bioinformatics plays a crucial role in identifying sepsis-related biomarkers associated with cardiac dysfunction and disease progression [18]. Common bioinformatics approaches utilized include differential gene expression analysis, protein-protein interaction (PPI) network construction, and pathway enrichment analysis, all of which aim to provide valuable insights into the biological processes linking sepsis and heart failure. Additionally, by integrating multi-omics data, these methods facilitate the development of predictive models that can identify key genes and pathways related to both conditions [19]. This approach not only enhances our understanding of the molecular interactions between sepsis and heart failure but also highlights potential biomarkers for early diagnosis and novel therapeutic targets for intervention.

In this study, we performed a multi-dataset analysis and applied elastic net regularization to develop a predictive model based on sepsis-related gene expression profiles to predict the occurrence of HF. Furthermore, we analyzed the immune infiltration patterns in HF patients to explore how variations in immune profiles may be associated with disease progression. Through comprehensive bioinformatic analysis and validation across independent datasets, we aim to enhance the understanding of the molecular mechanisms linking sepsis-related pathways to HF and to provide reliable tools for early diagnosis and risk stratification.

2. Methods

2.1. Data acquisition, preprocessing, and batch effect correction

We retrieved three sepsis-related gene expression datasets from the Gene Expression Omnibus (GEO): GSE65682, GSE54514, and GSE95233, which included samples from both sepsis patients and healthy controls. To ensure data uniformity, we conducted preprocessing that involved normalization and log transformation, making the datasets amenable for comparative analysis. Batch effects, inherent in the integration of multiple datasets, were initially assessed using Principal Component Analysis (PCA) and density plots, revealing dataset-specific clustering and distribution variations. To address these batch effects, we employed the ‘Combat’ algorithm from the ‘sva’ package in R, which standardized means and variances across datasets, thereby enhancing data comparability for subsequent analyses [19]. We then performed differential expression analysis to identify key genes dysregulated in sepsis versus controls, with a significance threshold set at p < 0.05. Volcano plots were created to visualize the distribution of differentially expressed genes, illustrating both up-regulated and down-regulated genes in each dataset.

2.2. Identification and dimensionality reduction of sepsis-related gene expression patterns

Three datasets (GSE65682, GSE54514, and GSE95233) were retrieved from the GEO database to identify sepsis-related genes. Venn diagrams were employed to determine the overlap of up-regulated and down-regulated genes across datasets. To effectively visualize gene expression differences, we calculated the mean expression and standard error of the up-regulated and down-regulated genes within the same groups. PCA was performed to evaluate the inter-cohort distances, offering a summary of the overall variance in gene expression. Additionally, we normalized the expression profiles for each dataset using z-score transformation and applied the ‘prcomp’ function to perform dimensionality reduction. Finally, a heatmap was generated to illustrate the expression levels of sepsis-related genes across all samples, providing insights into inter-individual variability.

2.3. PPI network construction and module analysis of sepsis-related genes

We utilized the STRING database (https://cn.string-db.org/) to construct PPI networks for the differentially expressed sepsis-related genes. STRING is a widely used platform for integrating and visualizing known and predicted protein-protein interactions, facilitating the exploration of cellular pathways and molecular mechanisms. Separate PPI networks were generated for up-regulated and down-regulated sepsis-related genes to uncover interaction patterns relevant to the pathogenesis of sepsis. To further investigate potential functional modules within these networks, we employed the ‘dynamicTreeCut’ algorithm in R, setting the minimum module size to two genes. This approach enabled the identification of cohesive gene clusters that may share related biological functions or participate in common signaling pathways.

2.4. GO and KEGG pathway enrichment analysis of sepsis-related genes

Gene Ontology (GO) enrichment analysis was conducted to investigate the biological processes, cellular components, and molecular functions associated with up-regulated and down-regulated sepsis-related genes. Separate GO analyses were performed for both gene groups to identify functional distinctions. To further explore the involvement of these genes in signaling pathways, we carried out the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. For improved clarity and interpretability, similar KEGG terms were merged, providing a concise overview of the enriched pathways. GO and KEGG enrichment analyses revealed several significantly enriched biological pathways. Pathways with a p-value < 0.05 and false discovery rate (FDR) < 0.05 were considered statistically significant.

2.5. Development of a predictive model for HF using sepsis-related genes

We developed a predictive model for HF using three publicly available datasets: GSE57345, GSE141910, and GSE5406, focusing on sepsis-related genes. The elastic net regularization method, which combines ridge regression and Lasso, was utilized to fit a generalized linear model using the ‘glmnet’ package in R [20]. To ensure data consistency, batch effects across datasets were corrected with the ‘ComBat’ algorithm, retaining only common genes for further analysis. The elastic net penalty parameter was set to α = 0.9, balancing Lasso and ridge regression. Cross-validation within the training dataset was employed to identify the optimal regularization parameter, lambda, which dictates the degree of shrinkage in model fitting [21]. Furthermore, a leave-one-study-out validation method was used to assess the model’s robustness across different training subsets. Genes selected by the elastic net were then integrated using logistic regression to create the final predictive model, which was evaluated on testing datasets to confirm its reliability in predicting HF.

2.6. Differential expression analysis, ROC analysis, and PPI network construction of model genes

We performed differential expression analysis on the six model genes to compare their expression between HF and control samples across both training and validation datasets. Receiver operating characteristic (ROC) curve analysis was used to evaluate the predictive performance of the constructed risk score relative to individual model genes. Immune checkpoint genes were found to be negatively correlated with the risk score. To provide a more detailed breakdown, we compared the expression levels of immune checkpoint genes between the high- and low-risk groups. Several checkpoint molecules, including PDCD1 (PD-1), CD274 (PD-L1), CTLA4, LAG3, and others, were significantly changed in the high-risk group. These results are illustrated in S1 Fig. Additionally, we explored potential PPIs involving the model genes by identifying interacting proteins and calculating cumulative interaction scores based on multiple layers of supporting evidence. The strength of each interaction was represented by the length of the connecting lines, with shorter lines indicating stronger evidence. Proteins positioned closer to the center of the network were assigned higher interaction confidence, reflecting greater biological relevance.

2.7. Immune infiltration quantification and correlation analysis

We utilized three immune infiltration quantification methods—CIBERSORT, IPS, and xCell—to comprehensively assess immune cell composition and immune-related activity within the training dataset. These complementary approaches provided detailed insights into immune landscape variations associated with HF. Additionally, correlation analyses were performed to evaluate the associations between the risk score and 46 immune-related metrics. To further explore immune regulatory dynamics, we assessed the correlation between the risk score and the expression of immune checkpoint genes, as well as its relationship with human leukocyte antigen (HLA) family gene expression, offering insights into antigen presentation and immune modulation.

2.8. Sepsis mouse model

All animal experiments conducted in this study were approved by the Institutional Animal Care and Use Committee of the Hubei Provincial Center for Disease Control and Prevention. Male C57BL/6 mice (8−10 weeks) were subjected to cecal ligation and puncture (CLP) to induce sepsis. All mice were anaesthetised with a solution of 3% pentobarbital sodium. Subsequently, a 2-cm midline incision was made to expose the cecum using a scalpel. Then one-third of the ileum-cecum junction was ligated with 4−0 silk thread and punctured twice with an 18 G needle. Twenty-four hours after the successful construction of the model, the mice were euthanised, and the tissue samples were collected. During the euthanasia of the mice, we initially gave a sedative (5 mg/kg) through an intraperitoneal injection. Once the mice became calm and unconscious, we administered a lethal dose of pentobarbital sodium (150 mg/kg) via intravenous injection. We then observed the heart rate, respiration, and pupillary reflexes of the mice to verify their death shortly thereafter.

2.9. RNA extraction and qRT-qPCR

Total RNA was extracted from tissue samples using TRIzol (Invitrogen, USA) and converted to complementary DNA (cDNA) using a cDNA synthesis kit (Vazyme, China). The quantitative reverse transcription polymerase chain reaction (qRT-qPCR) was performed using SYBR Green qRT-PCR Master Mix (Vazyme China) and with GAPDH as the internal control. Primers used are listed in Supplementary Table S1.

2.10. Ethics approval and consent to participate

The animal experiment was approved by the Institutional Animal Care and Use Committee of the Hubei Provincial Center for Disease Control and Prevention. There are no human subjects in this article and informed consent is not applicable.

2.11. Statistical analysis

All statistical analyses of bioinformatics data were performed using R software (version 4.1.2). A significance level of p < 0.05 was deemed statistically significant. For cellular experimental data analysis, GraphPad Prism 9.0 software (GraphPad, San Diego, CA) was utilized. All experiments were conducted in triplicate, and results were expressed as mean ± standard deviation (SD). Statistical comparisons between the two groups were conducted using a t-test, with p-values below 0.05 considered statistically significant. To ensure result reproducibility, all experiments were repeated a minimum of three times.

3. Results

3.1. Multi-dataset integration and identification of sepsis-related genes

The sample distribution across the three datasets is presented in the petal diagram (Fig 1A), which delineates the proportions of sepsis and control samples, facilitating an overview of dataset composition. An UpSet plot (Fig 1B) illustrates the intersection and uniqueness of gene sets across the datasets, revealing overlaps that provide insights into shared molecular signatures. PCA analysis before batch correction (Fig 1C) shows distinct clustering of samples by dataset, indicating the presence of batch effects, while the density plot (Fig 1D) further corroborates these findings by demonstrating significant differences in data distributions. Following Combat correction through the scale function of the R package to normalize, the PCA plot (Fig 1E) confirms successful integration, as samples from different datasets now cluster together, suggesting the removal of batch effects. Additionally, the density plot after correction (Fig 1F) displays aligned distributions with comparable means and variances, further supporting the effectiveness of the batch effect correction. Differential expression analysis revealed a range of sepsis-associated genes, with volcano plots for GSE65682 (Fig 1G), GSE54514 (Fig 1H), and GSE95233 (Fig 1I) displaying the up-regulated genes in red and the down-regulated genes in blue. These results emphasize both the shared and unique molecular patterns across datasets, enhancing our understanding of the gene expression alterations that characterize sepsis.

Fig 1. Batch Effect Correction of Multi-Dataset Integration and Differential Expression Analysis.

Fig 1

(A) Petal diagram illustrating the sample size distribution for sepsis and control groups across GSE65682, GSE54514, and GSE95233. (B) UpSet plot depicting the intersection and unique gene sets among the three datasets. (C) PCA plot before batch correction, showing dataset-specific clustering, indicating batch effects. (D) Density plot illustrating significant differences in data distribution across datasets before batch correction. (E) PCA plot after Combat correction, demonstrating mixed clustering of samples from different datasets, confirming successful batch effect removal. (F) Density plot after batch correction, showing aligned data distributions with comparable means and variances across datasets. (G-I) Volcano plots for GSE65682 (G), GSE54514 (H), and GSE95233 (I), visualizing the up-regulated (red) and down-regulated (green) genes with p-value < 0.05.

3.2. Expression patterns and cohort clustering of sepsis-related genes

The Venn diagrams reveal the shared gene sets across datasets, identifying 340 up-regulated genes (Fig 2A) and 333 down-regulated genes (Fig 2B). The PCA plot based on the mean expression and standard error (Fig 2C) demonstrates a clear separation between sepsis patients and healthy controls, highlighting distinct molecular profiles between these groups. Dimensionality reduction using z-score normalization followed by PCA (Figs 2D-F) confirms that sepsis and control samples form distinct clusters within each dataset, preserving the biological differences. The heatmap of sepsis-related gene expression (Fig 2G) shows substantial inter-patient variability, reflecting the heterogeneous nature of sepsis at the molecular level.

Fig 2. Identification, Dimensionality Reduction, and Expression Visualization of Sepsis-Related Genes.

Fig 2

(A) Venn diagram showing the 340 up-regulated sepsis-associated genes common across the three datasets. (B) Venn diagram displaying the 333 down-regulated sepsis-associated genes shared across the datasets. (C) PCA plot illustrating the inter-cohort distances based on the mean expression and standard error of sepsis-related genes, demonstrating distinct separation between sepsis and control samples. (D-F) PCA plots for individual datasets (GSE65682, GSE54514, and GSE95233) after z-score normalization, showing distinct clustering of sepsis and control samples. (G) Heatmap of sepsis-associated gene expression across all samples, highlighting marked inter-patient variability.

3.3. PPI network insights and module identification of sepsis-related genes

The PPI network of up-regulated sepsis-related genes, shown in Fig 3A, reveals critical molecular interactions potentially contributing to sepsis pathogenesis. Similarly, the PPI network for down-regulated genes, presented in Fig 3B, highlights distinct interaction patterns among the identified proteins. Using the ‘dynamicTreeCut’ algorithm, we identified six functional modules within the PPI networks (Fig 3C), suggesting that genes within each module may be involved in related biological processes or participate in coordinated regulatory pathways. These findings provide further insights into the molecular architecture underlying sepsis.

Fig 3. PPI Network and Module Identification of Sepsis-Related Genes.

Fig 3

(A) PPI network of up-regulated sepsis-related genes, constructed using the STRING database, illustrating key molecular interactions and their potential roles in sepsis pathogenesis. (B) PPI network of down-regulated sepsis-related genes, visualizing distinct functional interactions among the proteins involved. (C) Module analysis of the PPI networks using the ‘dynamicTreeCut’ algorithm, identifying six distinct gene modules. Each module contains at least two genes, indicating functional coherence and potential relevance to shared biological processes.

3.4. GO and KEGG enrichment results of sepsis-related genes

GO enrichment analysis of the up-regulated sepsis-related genes demonstrated significant enrichment in pathways such as mitotic nuclear division, secretory granule, mitochondrial respirasome, and enzyme binding (Fig 4A). Conversely, the GO analysis of down-regulated genes revealed enrichment in pathways related to the regulation of metabolic processes, protein binding, nucleoplasm, and intracellular anatomical structures (Fig 4B). The KEGG pathway analysis provided complementary insights by merging similar terms, offering a comprehensive summary of the enriched pathways. In the merged KEGG analysis (Fig 4C), pathways enriched by up-regulated genes are represented by red bars, while those enriched by down-regulated genes are shown in blue, reflecting their distinct biological roles.

Fig 4. GO and KEGG Pathway Enrichment Analysis of Sepsis-Related Genes.

Fig 4

(A) GO enrichment analysis of up-regulated sepsis-related genes, highlighting enrichment in pathways such as mitotic nuclear division, secretory granule, mitochondrial respirasome, and enzyme binding. (B) GO enrichment analysis of down-regulated sepsis-related genes, showing enrichment in pathways including regulation of metabolic processes, protein binding, nucleoplasm, and intracellular anatomical structures. (C) Merged KEGG pathway enrichment analysis, with red bars representing pathways enriched by up-regulated genes and blue bars indicating pathways enriched by down-regulated genes.

3.5. Performance of the predictive model for HF using sepsis-related genes

Using the regularization parameter that minimized binomial deviance, we developed a binomial classifier from all samples in the training datasets (Fig 5A). The classifier was constructed based on the expression profiles of six key genes identified through elastic net regression (Fig 5B). To explore the relationship between these genes across datasets, we analyzed the correlation of their expression between the training and testing datasets (Fig 5C), providing insight into their expression patterns. An analysis of the genes with non-zero coefficients indicated that their expression patterns were nearly mutually exclusive (Fig 5D), suggesting that each gene contributed independently to the predictive model. To validate the performance of the classifier, we tested it on two independent datasets, GSE141910 and GSE5406. As shown in Fig 5E, the model effectively distinguished HF patients from healthy controls, demonstrating its predictive capacity across multiple datasets.

Fig 5. Performance and Validation of the Predictive Model for HF.

Fig 5

(A) Development of the binomial classifier using the regularization parameter that minimized binomial deviance in the training datasets. (B) Expression profiles of the six key genes used to construct the predictive model. (C) Correlation analysis of the expression levels of the six model genes between the training and testing datasets. (D) Analysis of genes with non-zero coefficients, showing that their expression profiles are nearly mutually exclusive. (E) Validation of the predictive model on independent datasets GSE141910 and GSE5406, confirming the model’s ability to differentiate HF patients from healthy controls.

3.6. Differential expression, ROC analysis, and PPI results of model genes

The differential expression analysis revealed that all six model genes exhibited significant expression differences between HF and control samples in the training dataset (Fig 6A), with these findings consistently validated in the independent validation dataset (Fig 6B). ROC curve analysis demonstrated that the risk score achieved superior predictive performance for HF compared to any individual gene in the training dataset with the highest AUC value, which indicates the high sensitivity and specificity of the risk score. (Fig 6C). Similar results were observed in both independent validation datasets, confirming the robustness of the risk score (Figs 6DE). The PPI network analysis identified several interacting proteins for the model genes, with three genes—GNMT, FURIN, and BEX1—exhibiting experimentally supported interactions (Figs 6F-H). Interaction scores were calculated to reflect the strength of supporting evidence, with shorter lines representing stronger interactions. Proteins located closer to the center of the network were assigned higher interaction confidence, indicating their biological significance.

Fig 6. Differential Expression, ROC Analysis, and PPI Network of Model Genes.

Fig 6

(A) Differential expression analysis of the model genes in the training dataset, showing significant differences between HF and control samples. (B) Differential expression analysis in the validation dataset, confirming the significant expression patterns observed in the training dataset. (C) ROC curve analysis in the training dataset, demonstrating that the risk score provides superior predictive performance for HF compared to individual model genes. (D-E) ROC curve analyses in two independent validation datasets, showing that the risk score consistently outperforms individual genes in predicting HF. (F-H) PPI network analysis of GNMT, FURIN, and BEX1, with interactions supported by experimental evidence. The length of the lines reflects the strength of interaction evidence, with shorter lines indicating stronger interactions.

3.7. Immune infiltration results and association with risk score

Immune infiltration analysis revealed significant differences in immune metrics between HF patients and healthy controls, with these differences becoming more pronounced at higher levels of the risk score (Fig 7A). Correlation analysis demonstrated that the risk score was significantly associated with most of the 46 immune-related metrics, indicating its broad impact on the immune landscape (Fig 7B). Furthermore, a significant negative correlation was observed between the risk score and immune checkpoint gene expression, suggesting impaired immune regulation (Fig 7C). In contrast, the risk score exhibited a significant positive correlation with the expression of HLA family genes, indicating enhanced antigen presentation capacity in individuals with higher risk scores (Fig 7D).

Fig 7. Immune Infiltration and Association with Risk Score in HF Patients.

Fig 7

(A) Immune infiltration analysis using CIBERSORT, IPS, and xCell, showing significant differences between HF patients and control samples, with more pronounced differences at higher risk score levels. (B) Correlation analysis between the risk score and 46 immune-related metrics, demonstrating significant associations. (C) Negative correlation between the risk score and immune checkpoint gene expression. (D) Positive correlation between the risk score and HLA family gene expression.

3.8. The expression levels of six key genes in sepsis models

As shown in Fig 8, the relative expression levels of GNMT, SEMA4B, FURIN, and RNASE2 were significantly lower in the sepsis group than those in the control group. However, the relative expression levels of BEX1, and EPHX2 were significantly higher in the sepsis group than those in the control group.

Fig 8. The Relative Expression Levels of Six Key Genes in Sepsis Models.

Fig 8

The qRT-qPCR results demonstrated that the expression levels of GNMT, SEMA4B, FURIN, and RNASE2 in the sepsis group (n = 9) were significantly lower than those of the control group (n = 9), whereas the relative expression levels of BEX1, and EPHX2 were significantly higher. **p 0.01, ***p 0.001, ****p 0.0001, t-test based p-value.

4. Discussion

In clinical medicine, sepsis and HF are two severe pathological conditions with a complex and interrelated relationship. Sepsis is a multifactorial syndrome, typically triggered by infection, resulting in a systemic inflammatory response and multi-organ dysfunction [22]. HF, characterized by the heart’s inability to pump sufficient blood to meet the body’s metabolic demands, can arise from various etiologies, including coronary artery disease, hypertension, and cardiomyopathy [23]. Sepsis has a profound impact on patients with HF, particularly those with HF with reduced ejection fraction (HFrEF). Studies show that individuals with HFrEF admitted for sepsis exhibit higher in-hospital mortality and increased 90-day readmission rates compared to patients without HF [24]. Additionally, studies have shown that the incidence of HF is higher in sepsis patients and that HF can worsen the prognosis of sepsis. Patients with HF may experience a higher risk of death when experiencing sepsis [25]. These findings underscore the bidirectional relationship between sepsis and HF, emphasizing the need for effective predictive models and targeted interventions to improve outcomes in this vulnerable patient population.

HF in septic patients is primarily driven by the release of cytokines, mitochondrial dysfunction, and tissue hypoxia, resulting in myocardial cell injury and death. During sepsis, a series of structural and functional alterations occur in myocardial mitochondria, leading to disturbances in cardiac energy metabolism. Oxidative stress and nitrosative stress can cause changes in the lipid components of mitochondrial membranes [26]. Reactive oxygen species (ROS) directly attack the mitochondrial membrane lipids in cardiomyocytes, resulting in lipid peroxidative damage and compromising the integrity of the inner mitochondrial membrane. The myocardial depression induced by sepsis may also be a consequence of the direct toxicity of sepsis mediators on myocardial cells. Myocardial dysfunction resulting from sepsis is one of the main reasons for the high mortality associated with sepsis, as it can induce heart failure through the modulation of mitochondrial dysfunction, metabolic changes, cell death, and signaling pathways [27].

In the early stages of sepsis, inflammatory cells are recruited to the sites of injury, leading to endothelial dysfunction, vascular occlusion, and the release of pro-inflammatory factors, degrading enzymes, and ROS [28]. Mitochondrial dysfunction is primarily due to increased ROS levels that disrupt the homeostatic concentrations within mitochondria, resulting in various reversible and irreversible toxic modifications of biomolecules, such as protein carbonylation and lipid peroxidation [29]. Simultaneously, excessive ROS and nitric oxide (NO) can damage the structure of the mitochondrial respiratory chain and exacerbate ROS biosynthesis [30,31]. The excess ROS generated by the myocardium itself or by infiltrating inflammatory cells alters intracellular signaling cascades, leading to severe oxidative stress within the cells.

The metabolic demands of sepsis require considerable energy derived from fat metabolism, amino acid metabolism, glucose metabolism, and absorption of energy from cellular metabolism to regulate immune function [32,33]. AMPK is a classical cellular energy sensor that reconnects metabolism and maintains redox balance. The regulation of cellular mechanisms by AMPK is highly relevant to septic myocardial injury [34,35]. Notably, AMPK activators have been explored as a novel approach to alleviate inflammation related to ROS-associated diseases, including sepsis-induced injuries and cardiovascular diseases.

Furthermore, ferroptosis and pyroptosis contribute to the pathogenesis of sepsis. Iron molecules promote the aggregation of ferritin on cell membranes through the HO-1 pathway; however, the activation of ferritin by iron leads to increased iron export, causing iron overload [36,37]. By regulating the key molecule GSDMD, pyroptosis activates the NLRP3 inflammasome and caspase-1-dependent apoptosis, contributing to myocardial dysfunction in sepsis.

In this study, we developed and validated a predictive model for HF using sepsis-related gene signatures, demonstrating robust performance across independent datasets. Our model, based on six key genes, significantly outperformed individual biomarkers in both training and validation datasets. Furthermore, immune infiltration analysis revealed distinct patterns in HF patients, with more pronounced immune changes observed at higher risk score levels. These findings provide new insights into the molecular links between sepsis and HF, offering potential tools for early diagnosis and risk stratification. The model, based on six key genes including EPHX2, BEX1, RNASE2, FURIN, SEMA4B, and GNMT identified through elastic net regularization, consistently outperformed individual biomarkers, highlighting the advantage of integrating multiple gene signatures into a composite risk score. Among these key genes, EPHX2 serves multiple roles in HF, influencing disease progression and clinical outcomes by affecting pathways such as PI3K/AKT and GSK3β signaling pathways [38–40]. BEX1 acts as an RNA-dependent mediator, stabilizing and enhancing the expression of pro-inflammatory mRNAs, thereby contributing to the progression of cardiac disease [41]. In addition, Martens et al. demonstrated that BEX1 is both necessary and sufficient to counteract viral replication in dissociated primary cardiomyocytes and mouse embryonic fibroblasts. BEX1 can interfere with the expression of coxsackievirus B3 (CBV3) by regulating the expression of interferon-beta in infected cells. This antiviral effect may have broader applicability, extending beyond CVB3 to include other viruses, such as influenza A and Sendai virus [42]. RNASE2, associated with subclinical chronic inflammation, can predispose individuals to acute cardiac complications [43,44]. FURIN expression is often elevated in HF, promoting BNP maturation and intensifying cardiac stress responses [45,46]. Additionally, the product of the SEMA4B gene, Sema4D, has emerged as a critical player in the pathophysiology of HF [47]. The ROC curve analysis further confirmed the model’s reliability, showing superior performance in distinguishing HF patients from controls across both training and validation datasets. Together, these findings underscore the relevance of these key genes in cardiac dysfunction and highlight the potential of this multi-gene model for early diagnosis and personalized risk stratification in HF patients.

In our study, In high-risk HF patients, immune checkpoint genes—responsible for regulating immune exhaustion and preventing excessive immune activation—are expressed at lower levels. This suggests that in these patients, a lack of immune suppression may drive persistent immune activation and inflammation, exacerbating cardiac dysfunction and contributing to disease progression [48,49]. In contrast, the positive correlation between the risk score and HLA gene expression indicates enhanced antigen presentation capacity. Research suggests that the expression of HLA class I antigens may contribute to immune escape mechanisms within the heart, allowing cardiac cells to evade immune surveillance and thereby exacerbating the progression of HF [50].

Despite our predictive model has strong performance and has been validated on independent datasets, there are still some limitations. The observational design limits the interpretation of causal relationships, and reliance on publicly available datasets may introduce bias, emphasizing the necessity of prospective, multicenter validation. Furthermore, while the model provides valuable insights for early diagnosis and risk stratification, further improvement by integrating other omics data such as proteomics or metabolomics can enhance its predictive accuracy and clinical applicability. While the selected characteristic genes may serve as biomarkers for HF, they have not been fully validated in clinical samples such as serum, and there is insufficient experimental evidence. Although our research findings have to some extent revealed the relationship between sepsis and HF, and identified relevant biomarkers, our study relies on public databases and cannot represent the entire global community. In the future, a larger global database of samples will be needed for more in-depth exploration and validation.

5. Conclusion

To summarize, our study demonstrates the potential of integrated multi-omics analysis in identifying sepsis-related gene signatures that improve predictive modeling of heart failure. Our findings highlight the importance of these gene signatures in elucidating the pathophysiology of heart failure, providing a foundation for future research and clinical interventions aimed at early detection and management.

Supporting information

S1 Fig. Comparison of Immune Checkpoint Gene Expression Levels between High- and Low-Risk Groups.

*P 0.05, **p 0.01, ***p 0.001.

(TIF)

pone.0326212.s001.tif (19.9MB, tif)
S1 Table. Primers for qRT-PCR.

(DOCX)

pone.0326212.s002.docx (12.2KB, docx)

Abbreviations

HF

Heart failure

DEG

Differentially expressed gene

EF

Ejection fraction

BNP

Brain natriuretic peptide

NT-proBNP

N-terminal pro-b-type natriuretic peptide

MRAs

Mineralocorticoid receptor antagonists

ET-1

Endothelin-1

PPI

Protein-protein interaction;

PCA

Principal Component Analysis

GEO

Gene Expression Omnibus

GO

Gene Ontology

KEGG

Kyoto Encyclopedia of Genes and Genomes

FDR

False discovery rate

ROC

Receiver operating characteristic

HFrEF

HF with reduced ejection fraction

ROS

Reactive oxygen species

NO

Nitric oxide

CBV3

Coxsackievirus B3

HLA

Human leukocyte antigen

CLP

Cecal ligation and puncture

cDNA

Complementary DNA

qRT-PCR

Quantitative reverse transcription polymerase chain reaction

Data Availability

Data is provided within the manuscript or supporting information files. All the raw data can be found at the following link: https://doi.org/10.57760/sciencedb.23650.

Funding Statement

The author(s) received no specific funding for this work.

References

  • 1.Shankar-Hari M, Harrison DA, Rubenfeld GD. Epidemiology of sepsis and septic shock in critical care units: comparison between sepsis-2 and sepsis-3 populations using a national critical care database. British Journal of Anaesthesia. 2017;119(4):626–36. [DOI] [PubMed] [Google Scholar]
  • 2.Gräff I, Goldschmidt B, Glien P, Dolscheid-Pommerich RC, Fimmers R, Grigutsch D. Validity of the Manchester Triage System in patients with sepsis presenting at the ED: a first assessment. Emerg Med J. 2017;34(4):212–8. doi: 10.1136/emermed-2015-205309 [DOI] [PubMed] [Google Scholar]
  • 3.Gotts JE, Matthay MA. Sepsis: pathophysiology and clinical management. BMJ. 2016;353:i1585. [DOI] [PubMed] [Google Scholar]
  • 4.Bloom MW, Greenberg B, Jaarsma T, Januzzi JL, Lam CSP, Maggioni AP, et al. Heart failure with reduced ejection fraction. Nat Rev Dis Primers. 2017;3:17058. doi: 10.1038/nrdp.2017.58 [DOI] [PubMed] [Google Scholar]
  • 5.Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801–10. doi: 10.1001/jama.2016.0287 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Gusti N, Heriansyah T, Saputra I. Association between admission blood sugar levels and length of stay among patients with acute heart failure: A cross-sectional study in Aceh, Indonesia. Narra X. 2023;1(2). [Google Scholar]
  • 7.Prana Jagannatha GN, Suastika LOS, Kosasih AM, de Liyis BG, Yusrika MU, Kamardi S, et al. Prognostic Value of Baseline Echocardiographic Parameters in Heart Failure With Improved vs Nonrecovered Ejection Fraction. CJC Open. 2023;5(12):859–69. doi: 10.1016/j.cjco.2023.08.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Castiglione V, Aimo A, Vergaro G, Saccaro L, Passino C, Emdin M. Biomarkers for the diagnosis and management of heart failure. Heart Fail Rev. 2022;27(2):625–43. doi: 10.1007/s10741-021-10105-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Sinardja CWD, Jagannatha GNP, De Liyis BG. Safety and efficacy of early beta-blocker initiation in acute heart failure and cardiogenic shock: systematic review and meta-analysis. The Egyptian Heart Journal. 2024;76(1):126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Adji AS, Widjaja JS, de Liyis BG. Effectiveness and safety of mineralocorticoid receptor antagonists in heart failure patients with and without diabetes: a systematic review and meta-analysis. Egypt Heart J. 2024;76(1):150. doi: 10.1186/s43044-024-00580-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Khoury J, Arow M, Elias A, Makhoul BF, Berger G, Kaplan M, et al. The prognostic value of brain natriuretic peptide (BNP) in non-cardiac patients with sepsis, ultra-long follow-up. J Crit Care. 2017;42:117–22. doi: 10.1016/j.jcrc.2017.07.009 [DOI] [PubMed] [Google Scholar]
  • 12.Zhu J, Song C, Cai T. The Relationship between Serum CXCL8 and ET-1 Expression Levels and Sepsis Complicated with Heart Failure. Cardiology Research and Practice. 2022;2022:1–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Peng C, Zhang Y, Lang X, Zhang Y. Role of mitochondrial metabolic disorder and immune infiltration in diabetic cardiomyopathy: new insights from bioinformatics analysis. J Transl Med. 2023;21(1):66. doi: 10.1186/s12967-023-03928-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Zhang D, Zhao K, Han T, Zhang X, Xu X, Liu Z, et al. Bisphenol A promote the cell proliferation and invasion ability of prostate cancer cells via regulating the androgen receptor. Ecotoxicol Environ Saf. 2024;269:115818. doi: 10.1016/j.ecoenv.2023.115818 [DOI] [PubMed] [Google Scholar]
  • 15.Kolur V, Vastrad B, Vastrad C, Kotturshetti S, Tengli A. Identification of candidate biomarkers and therapeutic agents for heart failure by bioinformatics analysis. BMC Cardiovasc Disord. 2021;21(1):329. doi: 10.1186/s12872-021-02146-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Guo L, Xu C-E. Integrated bioinformatics and machine learning algorithms reveal the critical cellular senescence-associated genes and immune infiltration in heart failure due to ischemic cardiomyopathy. Front Immunol. 2023;14:1150304. doi: 10.3389/fimmu.2023.1150304 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Yu Y-D, Xue Y-T, Li Y. Identification and verification of feature biomarkers associated in heart failure by bioinformatics analysis. Sci Rep. 2023;13(1):3488. doi: 10.1038/s41598-023-30666-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Li R, Guo C, Li Y, Qin Z, Huang W. Therapeutic targets and signaling mechanisms of vitamin C activity against sepsis: a bioinformatics study. Brief Bioinform. 2021;22(3):bbaa079. doi: 10.1093/bib/bbaa079 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2007;8(1):118–27. doi: 10.1093/biostatistics/kxj037 [DOI] [PubMed] [Google Scholar]
  • 20.Friedman J, Hastie T, Tibshirani R. Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw. 2010;33(1):1–22. doi: 10.18637/jss.v033.i01 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Hughey JJ, Butte AJ. Robust meta-analysis of gene expression using the elastic net. Nucleic Acids Res. 2015;43(12):e79. doi: 10.1093/nar/gkv229 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Rello J, Valenzuela-Sánchez F, Ruiz-Rodriguez M, Moyano S. Sepsis: A Review of Advances in Management. Adv Ther. 2017;34(11):2393–411. doi: 10.1007/s12325-017-0622-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Khaidirman SK, Hasan H, Andra CA, Lubis HA, Dangana A, Haykal TB. Relationship of left ventricular diastolic dysfunction with quality of life in heart failure patients with reduced ejection fraction (HFrEF). Narra J. 2024;4(2):e707. doi: 10.52225/narra.v4i2.707 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Mohamoud A, Abdallah N, Wardhere A, Teeri S, Ismayl M. Sepsis and septic shock outcomes and 90-day readmissions in heart failure with reduced ejection fraction: A national readmission database study. Curr Probl Cardiol. 2024;49(9):102696. doi: 10.1016/j.cpcardiol.2024.102696 [DOI] [PubMed] [Google Scholar]
  • 25.Herndon JM, Blackwell SB, Pinner N, Achey TS, Holder HB, Tidwell C. Assessment of Outcomes in Patients with Heart Failure and End-Stage Kidney Disease after Fluid Resuscitation for Sepsis and Septic Shock. J Emerg Med. 2024;66(6):e670–9. doi: 10.1016/j.jemermed.2024.02.001 [DOI] [PubMed] [Google Scholar]
  • 26.Song J, Fang X, Zhou K, Bao H, Li L. Sepsis‑induced cardiac dysfunction and pathogenetic mechanisms (Review). Mol Med Rep. 2023;28(6):227. doi: 10.3892/mmr.2023.13114 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Lelubre C, Vincent J-L. Mechanisms and treatment of organ failure in sepsis. Nat Rev Nephrol. 2018;14(7):417–27. doi: 10.1038/s41581-018-0005-7 [DOI] [PubMed] [Google Scholar]
  • 28.Galley HF. Oxidative stress and mitochondrial dysfunction in sepsis. Br J Anaesth. 2011;107(1):57–64. doi: 10.1093/bja/aer093 [DOI] [PubMed] [Google Scholar]
  • 29.Zhao M, Zheng Z, Zhang P, Xu Y, Zhang J, Peng S, et al. IL-30 protects against sepsis-induced myocardial dysfunction by inhibiting pro-inflammatory macrophage polarization and pyroptosis. iScience. 2023;26(9):107544. doi: 10.1016/j.isci.2023.107544 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Nong Y, Wei X, Yu D. Inflammatory mechanisms and intervention strategies for sepsis-induced myocardial dysfunction. Immun Inflamm Dis. 2023;11(5):e860. doi: 10.1002/iid3.860 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Lima MR, Silva D. Septic cardiomyopathy: A narrative review. Rev Port Cardiol. 2023;42(5):471–81. doi: 10.1016/j.repc.2021.05.020 [DOI] [PubMed] [Google Scholar]
  • 32.Nadamuni M, Venable AH, Huen SC. When a calorie isn’t just a calorie: a revised look at nutrition in critically ill patients with sepsis and acute kidney injury. Current Opinion in Nephrology & Hypertension. 2022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Costa NA, Pereira AG, Sugizaki CSA. Insights into thiamine supplementation in patients with septic shock. Frontiers in Medicine. 2022;8:805199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Assaf L, Eid AA, Nassif J. Role of AMPK/mTOR, mitochondria, and ROS in the pathogenesis of endometriosis. Life Sci. 2022;306:120805. [DOI] [PubMed] [Google Scholar]
  • 35.Zhang Y, Yin K, Wang D, Wang Y, Lu H, Zhao H, et al. Polystyrene microplastics-induced cardiotoxicity in chickens via the ROS-driven NF-κB-NLRP3-GSDMD and AMPK-PGC-1α axes. Sci Total Environ. 2022;840:156727. [DOI] [PubMed] [Google Scholar]
  • 36.Huo L, Liu C, Yuan Y, Liu X, Cao Q. Pharmacological inhibition of ferroptosis as a therapeutic target for sepsis-associated organ damage. Eur J Med Chem. 2023;257:115438. doi: 10.1016/j.ejmech.2023.115438 [DOI] [PubMed] [Google Scholar]
  • 37.Zhou P, Zhang S, Wang M. The induction mechanism of ferroptosis, necroptosis, and pyroptosis in inflammatory bowel disease, colorectal cancer, and intestinal injury. Biomolecules. 2023;13(5):820. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Oni-Orisan A, Cresci S, Jones PG, Theken KN, Spertus JA, Lee CR. Association between the EPHX2 p.Lys55Arg polymorphism and prognosis following an acute coronary syndrome. Prostaglandins Other Lipid Mediat. 2018;138:15–22. doi: 10.1016/j.prostaglandins.2018.07.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Zhu X, Li Y, Yu T, Li S, Chen M. A hypothesis-driven study to comprehensively investigate the association between genetic polymorphisms in EPHX2 gene and cardiovascular diseases: Findings from the UK Biobank. Gene. 2022;822:146340. doi: 10.1016/j.gene.2022.146340 [DOI] [PubMed] [Google Scholar]
  • 40.Edin ML, Gruzdev A, Bradbury JA, Graves JP, Muse GW, Goulding DR, et al. Overexpression of soluble epoxide hydrolase reduces post-ischemic recovery of cardiac contractile function. Biochem Pharmacol. 2024;228:116237. doi: 10.1016/j.bcp.2024.116237 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Accornero F, Schips TG, Petrosino JM, Gu S-Q, Kanisicak O, van Berlo JH, et al. BEX1 is an RNA-dependent mediator of cardiomyopathy. Nat Commun. 2017;8(1):1875. doi: 10.1038/s41467-017-02005-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Martens CR, Dorn LE, Kenney AD, Bansal SS, Yount JS, Accornero F. BEX1 is a critical determinant of viral myocarditis. PLoS Pathog. 2022;18(2):e1010342. doi: 10.1371/journal.ppat.1010342 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Ong EZ, Koh CWT, Tng DJH, Ooi JSG, Yee JX, Chew VSY, et al. RNase2 is a possible trigger of acute-on-chronic inflammation leading to mRNA vaccine-associated cardiac complication. Med. 2023;4(6):353-360.e2. doi: 10.1016/j.medj.2023.04.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Li J, Zhang X, Ren P, Wu Y, Wang Y, Zhou W, et al. Landscape of RNA-binding proteins in diagnostic utility, immune cell infiltration and PANoptosis features of heart failure. Front Genet. 2022;13:1004163. doi: 10.3389/fgene.2022.1004163 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Wichaiyo S, Koonyosying P, Morales NP. Functional Roles of Furin in Cardio-Cerebrovascular Diseases. ACS Pharmacol Transl Sci. 2024;7(3):570–85. doi: 10.1021/acsptsci.3c00325 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Ichiki T, Boerrigter G, Huntley BK, Sangaralingham SJ, McKie PM, Harty GJ, et al. Differential expression of the pro-natriuretic peptide convertases corin and furin in experimental heart failure and atrial fibrosis. Am J Physiol Regul Integr Comp Physiol. 2013;304(2):R102-9. doi: 10.1152/ajpregu.00233.2012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Wu B, Xu C, Xu C, Qiu L, Gao J-X, Li M, et al. Inhibition of Sema4D attenuates pressure overload-induced pathological myocardial hypertrophy via the MAPK/NF-κB/NLRP3 pathways. Biochim Biophys Acta Mol Basis Dis. 2024;1870(3):166944. doi: 10.1016/j.bbadis.2023.166944 [DOI] [PubMed] [Google Scholar]
  • 48.Kushnareva E, Kushnarev V, Artemyeva A, Mitrofanova L, Moiseeva O. Myocardial PD-L1 Expression in Patients With Ischemic and Non-ischemic Heart Failure. Front Cardiovasc Med. 2022;8:759972. doi: 10.3389/fcvm.2021.759972 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Martins S, António N, Carvalheiro T. Reduced numbers of regulatory T cells in chronic heart failure seems not to be restored by cardiac resynchronization therapy. BMC Cardiovascular Disorders. 2023;23(1):89. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Hiraoka N, Ino Y, Hori S, Yamazaki-Itoh R, Naito C, Shimasaki M, et al. Expression of classical human leukocyte antigen class I antigens, HLA-E and HLA-G, is adversely prognostic in pancreatic cancer patients. Cancer Sci. 2020;111(8):3057–70. doi: 10.1111/cas.14514 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Muhammad Iqhrammullah

PONE-D-24-53311Integrated Multi-Omics Analysis and Predictive Modeling of Heart Failure Using Sepsis-Related Gene SignaturePLOS ONE

Dear Dr. Li,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by May 08 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Muhammad Iqhrammullah, Ph.D

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1.Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. To comply with PLOS ONE submissions requirements, in your Methods section, please provide additional information regarding the experiments involving animals and ensure you have included details on (1) methods of sacrifice, (2) methods of anesthesia and/or analgesia, and (3) efforts to alleviate suffering.

3. We note that your Data Availability Statement is currently as follows: All relevant data are within the manuscript and in Supporting Information files.

Please confirm at this time whether or not your submission contains all raw data required to replicate the results of your study. Authors must share the “minimal data set” for their submission. PLOS defines the minimal data set to consist of the data required to replicate all study findings reported in the article, as well as related metadata and methods (https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition).

For example, authors should submit the following data:

- The values behind the means, standard deviations and other measures reported;

- The values used to build graphs;

- The points extracted from images for analysis.

Authors do not need to submit their entire data set if only a portion of the data was used in the reported study.

If your submission does not contain these data, please either upload them as Supporting Information files or deposit them to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories.

If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. If data are owned by a third party, please indicate how others may request data access.

4. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager.

5. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: A review of the manuscript entitled “Integrated Multi-Omics Analysis and Predictive Modeling of Heart Failure Using Sepsis-Related Gene Signature”

1. The authors should improve their literature review by including recently published papers. Additionally, besides summarizing previous work in the topic, the authors should link their approach with previous studies by highlighting the state-of-the-art and gap in the literature.

2. (page 9): These sentences “HF is a prevalent cardiovascular disorder that impacts the health of millions worldwide…” also share the same idea with a study by Gusti et al. entitled “Association between admission blood sugar levels and length of stay among patients with acute heart failure: A cross-sectional study in Aceh, Indonesia” https://doi.org/10.52225/narrax.v1i2.75. Kindly include this reference to make the sentences stronger.

3. (page 22): This sentence “HF, characterized by the heart’s inability to pump sufficient blood to meet the body’s metabolic demands, can arise from various etiologies, including coronary artery disease, hypertension, and cardiomyopathy” will be more significant if it’s also supported by another relevant study. Please check https://pubmed.ncbi.nlm.nih.gov/39280297/

4. What is the conclusion of this study?

Reviewer #2: This is an interesting predictive model development study on Predictive Modeling of Heart Failure using Sepsis-related gene signature in China. The topic is interesting and the authors present a novel and well-defined methodology, and present the data adequately therefore I recommend the journal to publish this paper.

I have several major concerns and a few suggestions on how to improve the readability of the manuscript. General comments:

This study has demonstrated areas which are covered by this journal therefore publications is recommended. The main objective of the current review, according to the authors, is to provide reliable tools for early diagnosis and risk stratification. However, the authors have not robustly stated why is there a need of reliable tools for early diagnosis and risk stratification based on bioinformatics? Could this idea be implemented worldwide? This should also be addressed in the manuscript.

Specific comments:

1. Abstract:

- Abstract has been written well

2. Introduction:

- The author have argued well the reason why this study has to be conducted using valid and clear statement. However, robust explanation regarding the need for bioinformatics-based reliable tools for early diagnosis and risk stratification is still expected from the author, especially for the world population. The author could benchmark into several gene related studies.

- Please add more citations on key recent studies or relevant prior work in the field, such as studies on heart failure biomarkers or predictive modeling approaches?

- The author could improve elaborations on how this study could not only help identify HF risk in sepctic patients using reliable predictive models, but could impact in similar settings or other regions or countries, thus this explanation should be provided.

3. Methods

- The methods is too long, please simplify

- Please also elaborate robustly about what statistical analysis was done in every step in this study.

- “Additionally, we explored potential PPIs involving the model genes by identifying interacting proteins and calculating cumulative interaction scores based on multiple layers of supporting evidence.” � Please add citations

- If possible, please provide external validation methods

4. Results

- The authors have shown results clearly. However, is it possible to assess the risk factors with Odds ratio or any other effect size? Please add if possible.

- “ROC curve analysis demonstrated that the risk score achieved superior predictive performance for HF compared to any individual gene in the training dataset “ Please provide any numbers which supported this statement.

- If possible, please provide other parameter than just ROC curves. For instance AUC curves? (if possible)

- If possible, please add external validation results done in this study.

5. Discussion and Recommendations

- Discussion is too long, please shorten the discussion.

- While the clinical importance of sepsis and HF is well-explained, it may be useful to briefly mention why predictive modeling in this context is so crucial. Please elaborate more on the mechanisms underlying the bidirectional relationship, perhaps touching on immune dysregulation, metabolic pathways, or inflammatory processes.

- The interpretation of the findings is generally clear, but more explicit connections between the results and the broader clinical implications could strengthen the discussion. For instance, when introducing each key gene, consider highlighting how its specific role might influence treatment strategies or prognosis in sepsis-related HF.

- Please provide a bit more detail of specific metrics. For instance accuracy, sensitivity, or specificity. Please also provide a brief comparison to existing models (if available) to highlight how this model would improves compared current approaches.

- Are each gene’s role specifically in sepsis-related heart failure? Or Are these genes implicated in other cardiovascular diseases or other inflammatory conditions?

- If possible, please provide wide implementations and recommendations to improve readability of the paper

- Consider expanding on the clinical significance of immune checkpoint modulation. Could immune checkpoint inhibitors or immune modulation therapies potentially be explored as adjuncts in HF patients with sepsis?

6. Conclusion

- Conclusion is strong and well written. Please add what should be the clinical implications after this study.

7. Language

- Good

Reviewer #3: Overall, I think this manuscript merits publications. Great job! Although, there are some suggestions and questions for clarification.

Abstract

• The model development process is not clearly outlined—what were the inclusion criteria for key genes? How was performance assessed beyond ROC analysis?

• "superior performance compared to individual genes" lacks specificity. Provide quantitative results (e.g., AUC values) instead of qualitative statements.

• The claim that the model provides "valuable insights into molecular mechanisms" is broad and unsubstantiated without mentioning key pathways or biological processes.

• The abstract does not emphasize what is novel about this study compared to previous research. Is this the first study linking sepsis-related genes to HF prediction?

Introduction

• In depth explanation about HF itself is needed, please cite https://doi.org/10.1016/j.cjco.2023.08.006, https://doi.org/10.1186/s43044-024-00558-3, and https://doi.org/10.1186/s43044-024-00580-5

• While sepsis-induced cardiac dysfunction is acknowledged, the introduction lacks a thorough discussion on why sepsis-related genes are relevant to predicting HF.

• The introduction should include a stronger rationale for focusing on sepsis-specific gene signatures rather than broader inflammatory or cardiac biomarkers.

• Emphasize the knowledge gap in existing HF predictive models and why sepsis-related genes might improve upon them.

• The shift from discussing clinical aspects of HF to bioinformatics lacks coherence. Clearly state why an integrative multi-omics approach is needed and how it surpasses existing predictive models.

Methods

• The manuscript does not explain why these specific sepsis datasets were chosen. Were alternative datasets available?

• It is unclear whether the HF datasets used for validation match the demographic/clinical characteristics of the sepsis datasets. A lack of harmonization could introduce biases.

• How was the effectiveness of ComBat assessed post-correction? Did the batch effect correction introduce data distortion or information loss?

• The PCA analysis is described, but it is unclear how much variance was explained by the principal components.

• What was the impact of dimensionality reduction on model performance? Were genes retained based solely on statistical separation, or was biological relevance considered?

• The manuscript does not state how PPI analysis contributes to the study’s predictive modeling. Was it used to refine gene selection, or was it merely exploratory?

• The choice of the ‘dynamicTreeCut’ algorithm is not justified. Were alternative clustering methods (e.g., WGCNA) considered?

• The manuscript states that similar KEGG terms were merged, but this lacks transparency. What criteria were used for merging?

• The results should specify which pathways were enriched and discuss their relevance to HF. A simple list of pathways is not informative without interpretation.

• How were genes selected for inclusion in the final model? Was feature selection performed?

• The manuscript states that batch effects were corrected before model training, but does not clarify whether this was done separately for training and test sets.

• The manuscript mentions leave-one-study-out validation but does not clarify whether performance remained stable across different training subsets.

• Were genes selected based on statistical significance, biological relevance, or predictive importance in the model?

• ROC analysis alone is insufficient to assess model utility. Metrics such as precision-recall curves, calibration plots, or decision curve analysis should be provided.

Results

• The section describes overlaps in gene sets but does not elaborate on their biological significance in sepsis or heart failure. Are these overlapping genes known to play a role in inflammation or cardiac dysfunction?

• While PCA and z-score normalization are mentioned, it is unclear how batch-corrected expression values were standardized across datasets. Was cross-validation performed to ensure consistency?

• The heatmap shows inter-patient variability, but no quantitative measures (e.g., variance analysis) are provided to assess whether specific patient subgroups contribute disproportionately to the observed heterogeneity.

• The GO and KEGG results mention enriched pathways but fail to provide enrichment scores, p-values, or FDR-adjusted values. The significance of these pathways remains unclear without statistical support.

• While the model was tested on independent datasets, there is no mention of performance metrics beyond "effective distinction." Metrics such as AUC-ROC, sensitivity, specificity, or F1-score should be reported for evaluation.

• It is unclear whether cross-validation was performed to ensure the generalizability of the model. Were hyperparameters optimized using an independent validation set, or was the model trained and tested on overlapping samples?

• How does it compare to existing HF biomarkers?

• The text states that immune checkpoint genes are negatively correlated with risk score, but does not specify which immune checkpoints are affected. A more detailed breakdown is required.

Discussion

• The discussion largely reiterates known relationships between sepsis and HF but does not sufficiently integrate the study’s unique contributions. How do the identified genes improve current understanding of sepsis-induced HF?

• The discussion claims that immune infiltration changes are associated with HF risk but does not explore the underlying pathways responsible for these alterations. Which immune cell types are most affected? What cytokines or signaling pathways are implicated?

• While the predictive model is statistically validated, there is no discussion on how it could be used in clinical practice. Are there potential biomarkers that could be tested in blood samples? How does this model compare to traditional HF risk scoring systems?

• Were there any outliers or misclassified samples that affected the model’s performance?

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: No

Reviewer #2: Yes:  Ayers Gilberth Ivano Kalaij

Reviewer #3: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step.

PLoS One. 2025 Jun 17;20(6):e0326212. doi: 10.1371/journal.pone.0326212.r003

Author response to Decision Letter 1


17 Apr 2025

Dear Editor and reviewers:

Thank you very much for your detailed constructive and active comments on our manuscript.

According to each comment from reviewers, we have revised the manuscript carefully and made corresponding changes point by point. All the changes including the text and tables have been added and labeled in yellow in the revised manuscript according to this response. The list of changes has been itemized and explained in the "Response to Reviewers" file.

Thanks again for your constructive suggestions. Thanks for your kind consideration of our article again. If you have any questions about the manuscript, please feel free to contact me.

Sincerely yours,

Fei Li

Email: lifeilifeiicu@163.com

Attachment

Submitted filename: Response to Reviewers.docx

pone.0326212.s004.docx (30.9KB, docx)

Decision Letter 1

Muhammad Iqhrammullah

Integrated Multi-Omics Analysis and Predictive Modeling of Heart Failure Using Sepsis-Related Gene Signature

PONE-D-24-53311R1

Dear Dr. Li,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager®  and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Muhammad Iqhrammullah, Ph.D

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #3: Accept. I think the authors have done the revision in a concise and direct manner. I wish them goodluck.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #3: No

**********

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Comparison of Immune Checkpoint Gene Expression Levels between High- and Low-Risk Groups.

    *P 0.05, **p 0.01, ***p 0.001.

    (TIF)

    pone.0326212.s001.tif (19.9MB, tif)
    S1 Table. Primers for qRT-PCR.

    (DOCX)

    pone.0326212.s002.docx (12.2KB, docx)
    Attachment

    Submitted filename: Response to Reviewers.docx

    pone.0326212.s004.docx (30.9KB, docx)

    Data Availability Statement

    Data is provided within the manuscript or supporting information files. All the raw data can be found at the following link: https://doi.org/10.57760/sciencedb.23650.


    Articles from PLOS One are provided here courtesy of PLOS

    RESOURCES